Oncobiologics, which develops biotherapeutics for cancer and immune system diseases, has opened a 25,000-square-foot research center in Cranbury that could bring 40 new jobs immediately and as many as 200 by the end of 2012.
The company held its ribbon cutting ceremony on October 14, when it announcd its intention to create jobs. Oncobiologics also has signed two major agreements totaling $80 million to help get it off the ground.
The company has signed with Parilis Biopharmaceuticals, an early-stage biotech company, to provide worldwide licensing for an undisclosed biotherapeutic product. It also has signed a deal with an undisclosed American pharma giant to conduct research into monoclonal antibodies. The identity of the pharma firm was not disclosed due to confidentiality terms in the agreement. –Scott Morgan
#b#Oncobiologics#/b#, 7 Clarke Drive, Cranbury 08512; 609-619-3990; fax, 609-619-3980. Pankaj Mohan, founder and CEO. www.oncobiologics.com